Influence of Circadian Clock on Hormonal, Metabolic, Neurocognitive Markers in Adolescents With and Without Diabetes
Influence of Circadian Clock on Diurnal Dietary Intake, Glucose Variability, Time Spent in Range, and Neuro-cognitive Achievements Among Adolescents With and Without Type 1 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Marianna Rachmiel, M.D
- Phone Number: +972-537346636
- Email: rmarianna@gmail.com
Study Contact Backup
- Name: Avital Leshem
- Phone Number: +972-528303012
- Email: childendo.research@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Families living in areas with high access to medical care.
- Age: 12-18 years old
- T1D diagnosis for longer than 1 year
- speaking fluent Hebrew
Exclusion Criteria:
- significant renal or liver function abnormalities
- head injuries,
- epileptic episodes
- psychiatric medications
- lack of Hebrew abilities
- disagreement to comply with all the study requests
- history of more than one episode of a severe hypoglycemic event in the past, including loss of consciousness or more than one episode of diabetic ketoacidosis.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Normal Circardian rhythm
Regular night sleep, with at least 7 hours length of sleep.
|
Normal day/ night sleep cycle
|
|
Reversed circadian rhythm
Night/day circadian clock is opposite, with at least 7 hours length of sleep
|
Revered day/ night sleep cycle
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Affects of reversal circadian clock on neuro cognitive tasks performance among healthy and T1D patients, according to glucose
Time Frame: 2 years
|
Score of neurocognitive tests for executive function according to day/night sleeping pattern session
|
2 years
|
|
Affects of reversal circadian clock on Glucose Variability parameters among both healthy and T1DM adolescents .
Time Frame: 2 years
|
Time spent in range of glucose of 70-180 mg/dl according to day/night sleeping pattern
|
2 years
|
|
Affects of reversal circadian clock on sleep quality among both healthy and T1DM adolescents (mainly T1DM), controlled for BMI-SDS, and mean HbA1c in T1D patients.
Time Frame: 2 years
|
Quality of sleep according to PSQI, according to day/night sleeping pattern
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Melatonin profile according to night/day sleep cycle among healthy and among T1D patients
Time Frame: 2 years
|
Differences in levels of melatonin in nmol/l between sessions and between health and T1D patients
|
2 years
|
|
Temperature according to night/day sleep cycle among healthy and among T1D patients
Time Frame: 2 years
|
Differences in peripheral body temperature (celzius) between sessions and between health and T1D patients
|
2 years
|
|
EEG registration in accordance with the circadian curve and neurocognitive achievements
Time Frame: 2 years
|
Power of high frequency amplitude between night/sleep sessions among T1D and healthy
|
2 years
|
|
MRI structural changes
Time Frame: 2 years
|
DT1-MRI trajectoris areas of supra-chiasmatic nuclei sleeping pattern session
|
2 years
|
|
Hormonal profile according to night/day sleep cycle among healthy and among T1D patients
Time Frame: 2 years
|
Differences in levels of cortisol in nmol/l between sessions and between health and T1D patients
|
2 years
|
|
Metabolic parameters according to night/day sleep cycle among healthy and among T1D patients
Time Frame: 2 years
|
Differences in blood pressure (mmHG) between sessions and between health and T1D patients
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0291-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.